Net profit 1H24 +2.7x YoY, beat expectations
Q4营收和毛利率均创新高,单季净利润yoy+353%
产业运营利润yoy+66%,聚焦主业盈利能力提升
23Q1-3营收yoy+1.86%,线上线下多渠道有望持续发力
1H23 NBV beat consensus; interim dividend up 1.1% YoY reinforcing a long-run growth story
FY2023Q2业绩点评:经调净利润+74%yoy,国内疫情下业绩仍超预期
2024上半年净利YOY+16%,符合预期,麻醉线增长较快
股票业务与经纪引领业绩增长,扣非净利润YOY+72%
2024年净利YOY+47%,创新药快速增长,创新出海交易增厚利润
1H24 earnings down 27% YoY below our expectation; expect a better 2H24E